KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Net Cash Flow (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Net Cash Flow for 17 consecutive years, with $60.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 77.22% year-over-year to $60.4 million, compared with a TTM value of $371.4 million through Dec 2025, up 103.06%, and an annual FY2025 reading of $371.4 million, up 103.06% over the prior year.
  • Net Cash Flow was $60.4 million for Q4 2025 at Biomarin Pharmaceutical, up from $35.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $264.9 million in Q4 2024 and bottomed at -$293.8 million in Q3 2024.
  • Average Net Cash Flow over 5 years is $32.9 million, with a median of $17.7 million recorded in 2021.
  • The sharpest move saw Net Cash Flow plummeted 947.55% in 2023, then soared 1167.58% in 2025.
  • Year by year, Net Cash Flow stood at -$29.8 million in 2021, then fell by 24.16% to -$37.1 million in 2022, then grew by 28.11% to -$26.6 million in 2023, then surged by 1094.33% to $264.9 million in 2024, then plummeted by 77.22% to $60.4 million in 2025.
  • Business Quant data shows Net Cash Flow for BMRN at $60.4 million in Q4 2025, $35.6 million in Q3 2025, and $168.1 million in Q2 2025.